Radiopharmaceuticals

Bristol Myers Squibb to buy RayzeBio in $4.1 billion cash deal

Bristol Myers Squibb said it will acquire RayzeBio in an all-cash deal valued at $4.1 billion, adding to its cancer drug pipeline and strengthening its push into radiopharmaceuticals. The company…